This single-center study of 237 consecutive patients who relapsed after HCT found that one-year post-relapse survival (PRS) was significantly higher in patients receiving matched related and matched unrelated grafts compared to those receiving haploidentical donor transplants using post-transplant cyclophosphamide. The median age of patients was 49 years (range, 19-77) and the median time to relapse was 156 days (range, 12-2,465) after HCT. One-year PRS was worse among haploidentical recipients compared with matched related and matched unrelated HCT (17% vs. 46% vs. 40%, p<0.05). In a multivariate analysis, variables predictive of worse PRS included time to relapse (<3 vs. >3 months post-transplant), not receiving a donor lymphocyte infusion following relapse, and higher Dana-Farber disease risk index and HCT comorbidity index scores at the time of transplant.
Higher Post-Relapse Survival with Related or Unrelated HCT than Haploidentical HCT